Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
As Israeli Firm Publishes Full-Year Results
Feb 12 2021
•
By
Dean Rudge
Teva's generic operations in the US are worth around $4bn per year in revenues • Source: Shutterstock
More from Generics
More from Products